<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>De novo epigenetic changes at <z:chebi fb="0" ids="15358">histone</z:chebi> and DNA level that affect gene transcription in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> may be less random than we originally thought </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001909'>Leukemia</z:hpo> fusion proteins associated with specific chromosome translocations could mechanistically determine the epigenetic fate of specific target genes critical for <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis </plain></SENT>
<SENT sid="2" pm="."><plain>This seems to be the case with AML1-MTG16, a fusion protein resulting from the t(16;21) translocation, a hallmark of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Here we show that AML1-MTG16 blocks both myeloid differentiation and proliferation in the 32D/WT1-mouse myeloid cell line </plain></SENT>
<SENT sid="4" pm="."><plain>These biological effects can be traced to the AML1 and MTG16 moieties of the fusion protein, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Further, we show that AML1-MTG16 can induce epigenetic repressive changes at the <z:chebi fb="0" ids="15358">histone</z:chebi> and DNA level of the AML1 target gene Csf1r (c-fms), encoding the macrophage colony stimulating factor receptor </plain></SENT>
<SENT sid="6" pm="."><plain>We observed that, concomitant with Csf1r downregulation, 32D/WT1 cells lost the ability to undergo myeloid differentiation in response to the granulocyte macrophage colony-stimulating factor (GM-CSF) </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, there seems to be an association between AML1-MTG16-induced myeloid maturation block and epigenetic changes of a myeloid master gene </plain></SENT>
</text></document>